% | $
Quotes you view appear here for quick access.

BioMarin Pharmaceutical Inc. Message Board

you are viewing a single comment's thread.

view the rest of the posts
  • thirdmeinvestor thirdmeinvestor Mar 1, 2004 8:00 AM Flag


    The study found that 54% of patients who took their version (obtained from Schircks Lab) of 6R-BH4 had varying degrees of reduction in the blood PA level. Because there are 400 different mutations in PAH enzyme, it is not surprising that remaining 46% did not respond. BMRN's next product PHENYLASE should work for them. BH4 is only a cofactor to it.

92.02-0.77(-0.83%)Jul 26 4:00 PMEDT